opc 21268 has been researched along with Diabetes Mellitus, Type 2 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Miura, Y; Nakano, H; Nakayama, M; Suzuki, S; Tsuchida, H; Yamada, K; Yoshida, S | 1 |
| Iizuka, T; Nishikawa, T; Omura, M; Saito, I; Yoshida, S | 1 |
1 trial(s) available for opc 21268 and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Short-term clinical trial of 1-(1-[4-(3-acetylaminopropoxy)-benzoyl]-4-piperidyl)-3, 4-dihydro-2(1H)-quinolinone in patients with diabetic nephropathy. Possible effectiveness of the specific vasopressin V1 receptor antagonist for reducing albuminuria in p
Topics: Albuminuria; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Blood Glucose; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Heart Rate; Humans; Male; Middle Aged; Piperidines; Quinolones; Saline Solution, Hypertonic | 1996 |
1 other study(ies) available for opc 21268 and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
The effect of OPC-21268, an oral, nonpeptide arginine vasopressin V1 receptor antagonist, on a patient with congestive heart failure.
Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Blood Pressure; Diabetes Mellitus, Type 2; Female; Heart Failure; Heart Rate; Humans; Kidney Failure, Chronic; Piperidines; Quinolones | 1993 |